DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke

Information source: Burke Rehabilitation Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Stroke; Cerebrovascular Accident; Hemiparesis

Intervention: Armodafinil (Drug); Placebo (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Burke Rehabilitation Hospital

Official(s) and/or principal investigator(s):
Pasquale Fonzetti, MD, PhD, Principal Investigator, Affiliation: The Burke Rehabilitation Hospital

Summary

Armodafinil is an FDA approved medication with wakefulness-promoting properties. It is a relatively safe agent with interesting neurochemical effects on the catecholamine system, producing an improvement in cognitive function, particularly working memory in humans. When combined with intensive task-related training, armodafinil may accelerate motor recovery in chronic stroke patients. The primary aim of this study is to determine whether administration of armodafinil during subacute post-stroke rehabilitation will augment cortical plasticity and enhance motor recovery. The primary hypothesis suggests that cortical plasticity will be enhanced by armodafinil and, therefore, will induce an improvement in motor function and better performances on measures of motor control.

Clinical Details

Official title: Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Discharge

Change in Functional Independence Measure (FIM) from Baseline to Discharge

Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Day 100

Change in Functional Independence Measure (FIM) from Baseline to Day 100

Secondary outcome:

Timed 3-Minute Walk Test

NIH Stroke Scale (NIHSS)

9-Hole Peg Test

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- First clinical stroke, either cerebral infarction or intracerebral hemorrhage

- Severe hemiparesis as measured by a Fugl-Meyer motor scale score of 0-25

- Screening Motricity Index score of 0-83

- Date of stroke onset between 7 to 21 days prior to study inclusion

Exclusion Criteria:

- Age less than 18

- Previous clinical stroke

- Pregnant and/or nursing patients

- Major psychiatric history, including psychosis and history of substance abuse

- Dementia

- Known CNS pathology such as brain tumor

- Significant language dysfunction or severe neglect that hinders comprehension,

participation, and barrier to testing

- Seizures

- Left ventricular hypertrophy (LVH)

- Mitral valve prolapse (MVP)

- Severe chronic renal failure or severe hepatic failure

- History or current use of anti-epileptic medications, psychostimulants, or

neuroleptics

- Current use of diazepam, phenytoin, propranolol, tricyclic antidepressants, steroidal

contraceptives, cyclosporine, or theophylline

Locations and Contacts

The Burke Rehabilitation Hospital, White Plains, New York 10605, United States
Additional Information

Starting date: January 2008
Last updated: July 25, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017